Lupus

‼️More reasons why we should avoid steroids in #lupus patients @RheumNow #APLAR25 https://t.co/a5IeutJ5mi

Links:

sheila @RHEUMarampa( View Tweet )
The overall prevalence of #osteoporosis in SLE is ~33-40% and is due to several factors with GC therapy being one of them. Monitor DXA every 6-12 months (vs. 2 yrs for standard OP) ☝️Screen for GIOP ☝️Treat accordingly - once on GCs & esp w/long-term use @RheumNow #APLAR25 https://t.co/E9FJDHrBUo

Links:

sheila @RHEUMarampa( View Tweet )
Lessons Learned in Neuropsychiatric SLE Dr. Sheila Reyes, The Philippines, reports highlights from a session on neuropsychiatric systemic lupus erythematosus, presented at the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/Dh1GQnBhvg https://t.co/wX5FgpIq7C

Links:

Dr. John Cush @RheumNow( View Tweet )
Target

Hitting the Target: T2T Therapy in SLE

Sheila Reyes, MD

Treat-to-target strategies are not a new concept in rheumatology. It has shown to improve patient outcomes and quality of life in RA and PsA, and is now being increasingly adopted not only in SLE research but also in clinical practice. This article reviews key highlights from Dr. Eric Morand’s

Read Article
9 yr. study of anti-Ro52 & ILD pts -- 1,026 pts 15% Ro52+: interstitial pneumonia w/ autoimmune 48%, CTD-ILD 13%, idiopathic pulm fibrosis 10%, hypersens pneumonitis 6%, idiopathic ILD 24%. Ro52+ were younger w/ more autoimmune dz, +MSA Abs, ILD progression, death, & lung https://t.co/fuFfnaYIRd
Dr. John Cush @RheumNow( View Tweet )
Is it #lupus? Interesting study by @escheriKYA et al. showing comparable diagnostic performance of SLERPI (93%) in 🇵🇭 patients vs. SLICC and EULAR/ACR criteria A practical alternative tool that can be used by clinicians in a resource-limited setting 🤔 @RheumNow #APLAR25 https://t.co/xByBkjEr3r

Links:

sheila @RHEUMarampa( View Tweet )
3 yr study of FDA Adverse Event Reporting on anifrolumab shows following AEs- URIs, herpes zoster, infusion reactions, and potential new risks like dyspnea and pyrexia, not in the label. https://t.co/vP2YWGT2vR https://t.co/BruGBtXEBu

Links:

Dr. John Cush @RheumNow( View Tweet )
APLAR GRAY

SLE and Osteoporosis

Sheila Reyes, MD

In one of the SLE sessions at the APLAR 2025 Congress, Prof. Sandra Navarra discussed the assessment and management of osteoporosis in SLE patients, particularly glucocorticoid-induced osteoporosis (GIOP) and this article reviews the highlights and key takeaways from her talk.

Read Article
A new player in AIRD ThA age associated T helper cells Displaying both Cytotoxic & APC functions Correlation with disease activity in RA and SLE More research is needed to better characterize function but could be a promising therapeutic target @RheumNow #APLAR25 https://t.co/4SnY65tXpJ

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
This slide reflects the rheumatologist’s goals for treating #lupus Prof. Mosca also highlights the fact that achieving targets is as important as maintaining these treatment targets. @RheumNow #APLAR25 https://t.co/u8fw3fThXI

Links:

sheila @RHEUMarampa( View Tweet )
Prof. Eric Morand on the SLE T2T approach. Ultimate goal is remission but we know that not all patients achieve this state. Thru the T2T approach, low dse activity (LLDAS) is an acceptable target & a protective alternative goal @RheumNow #APLAR25 #Lupus https://t.co/vz7E5prps0

Links:

sheila @RHEUMarampa( View Tweet )
Optimizing outcomes of pregnancy in #lupus: 📌 all patients should undergo preconception counselling 📌 close monitoring by a multidisciplinary team - a ⬇️ cerebroplacental ratio reflects placental dysfunction #APLAR25 @RheumNow @rheumarhyme https://t.co/RSyqgpRTG5

Links:

sheila @RHEUMarampa( View Tweet )
@Lupusreference reviews clinical trials in LES, highlights key limitations of current outcome measures and propose a novel a clinical outcome in SLE based on « How patients feel function and survive » Very relevant to the human experience of having a chronic illness @RheumNow https://t.co/vM58C9KfQ3

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Long-term data from the 48-wk phase 2 SLEek study of upadacitinib +/- a BTK inhibitor elsubrutinib, in SLE pts, showed both arms effective (little added from BTK), @ 1yr, 127 pts maintained efficacy, GC dose and flare rates https://t.co/FbTHCGZ4pQ https://t.co/cATXVHsiXV

Links:

Dr. John Cush @RheumNow( View Tweet )
EULAR & European Respiratory Society have published clinical practice guidelines for ILD assoc w/ connective tissue diseases (SSc, RA, SjD, IIM, SLE, MCTD). 2 publications included Dz specific ILD management algorithms; use of Hi Res CT over Lung Bx; ILD risk factors

Dr. John Cush @RheumNow( View Tweet )

6 yr study of Dutch #SLE pts (n 221) - unemployment was high (54%) & increased over time. Employ ed assoc w/ supervisor support, regular working hrs, skill discretion, decision authority. Unemployment most from SLE Sxs (63%) & assoc w/ older, less education, Dz Dur, organ

Dr. John Cush @RheumNow( View Tweet )

High unemployment in Dutch SLE patients, linked to SLE Sxs & Dz duration. Supervisor support helps with employment. https://t.co/E5jqmUHqo7
Dr. John Cush @RheumNow( View Tweet )
Recombinant zoster vaccine effective in #SLE without flare. Retrospective Medicare & commercial claims data on pts given 2 RZV doses, matched 1:4 to unVAX. 3592 pts F?u ~1.5 yrs. Vax effectiveness 70% in Medicare; 54% commercial. SLE flare rates HR 0.91& 0.94. https://t.co/WCBOQhb4Ad
Dr. John Cush @RheumNow( View Tweet )
Lupus Core Dataset for Research SLE is a complex and potentially life-threatening autoimmune disease. Part of the complexity stems from how it can differ from person to person – giving rise to marked heterogeneity in not only manifestations, but also in disease course and https://t.co/jHD9L3Bc2Y
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

ILD Begins (8.29.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com. This week news on vaccines, safety of acetaminophen and more.

Read Article
New #therapy in #SLE #lupus https://t.co/TPeKxfw9hq

Links:

Dr hanady manasfi @hanadymanasfi( View Tweet )
research2.jpg

Lupus Core Dataset for Research

EurekAlert!

SLE is a complex and potentially life-threatening autoimmune disease. Part of the complexity stems from how it can differ from person to person – giving rise to marked heterogeneity in not only manifestations, but also in disease course and treatment response. To support better understanding

Read Article
Pills.JIA_.png

Antibiotics are not linked to Autoimmune disease in kids

EurekAlert!

The global incidence of autoimmune diseases among children has increased over the past few decades. A study published August 21st in the open-access journal PLOS Medicine by Ju-Young Shin at Sungkyunkwan University, Republic of Korea, and colleagues suggests that early

Read Article
Rheumatic Dz & HIV - Arthralgia: self limiting - HIV-assoc arthritis: mimics RA - Occurs w/ HIV: SpA, ReA, PsA - Less : IIM, vasculitis, opportunistic infxn https://t.co/Yf7jZ0icZw https://t.co/6FuJgvDYRF

Links:

Dr. John Cush @RheumNow( View Tweet )
Anifrolumab appears effective & safe in refractory Cutaneous LE. OL Study of 15 CLE, on HCQ, topical steroids, failed multiple DMARDs. All Rx w/ ANIF 300 mg IV q4wks. ALL improved, CLASI-A decr from 16 to 1 (p<0.001); CLASI-D decreased from 5 to 4 (p<0.001). DBPCT needed! https://t.co/umEYz0XDyt
Dr. John Cush @RheumNow( View Tweet )

Recent Blogs

CNS Lupus (NPSLE)

Jack Cush, MD
Cush RhTh CNS
29 yr. old woman with SLE and transverse myelitis. Is this NPSLE; how to diagnose? Read Post

Hydroxychloroquine for Everyone

Jack Cush, MD
ra.hands2_.JPG
Nearly 25 years ago, while lecturing on best therapies for rheumatoid arthritis (RA), I loudly stated that hydroxychloroquine was “useless” and, deservedly, I was “boo-ed” off stage. My point then was that rheumatologists needed to be aggressive, if not overly aggressive, in treating all RA patients. And my view was that HCQ was representative of under-treatment. I have reconsidered the use of HCQ in RA substantially in the last few years, based on its merit. Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×